The drugs used in the therapy of BC, pembrolizumab and atezolizumab, represent monoclonal antibodies targeting the checkpoint protein PD-1 (programmed cell death protein 1) and its ligand PD-L1 [12,14]. This evidence concerns the gene CD274 and breast cancer.